New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.
AstraZeneca and Abbott Extend Relationship to Include Co-Promotion of Trilipix
- Details
- Category: AstraZeneca
AstraZeneca and Abbott have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX, a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote TRILIPIX alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.
FDA approves Reclast® to prevent osteoporosis in postmenopausal women
- Details
- Category: Novartis
Reclast® (zoledronic acid 5 mg) Injection[*] has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose[1].
Schering-Plough Announces European Filing of SYCREST(R) (asenapine)
- Details
- Category: Product
Schering-Plough Corporation (NYSE: SGP) announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder.
New study first ever to directly compare once-daily Levemir® with another basal insulin analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has announced the first patient visit in a new head-to-head clinical trial of once-daily Levemir® against insulin glargine. This study is the first time the two basal insulins will be directly compared in an exclusively once-daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia in type 2 diabetes patients.
Genzyme Completes Transaction with Bayer HealthCare
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this promising multiple sclerosis (MS) therapeutic candidate. Genzyme is conducting two rapidly progressing phase 3 studies of alemtuzumab in relapsing-remitting MS patients.
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc. will collaboration to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 (ARRY-886*) from AstraZeneca. Preclinical evidence indicates that combined administration of these compounds could enhance their anticancer properties.
More Pharma News ...
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
- Abbott Named One of the Top 10 Companies for Scientists
- AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
- Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva®
- Nycomed Reports a Solid Start to 2009
- US Department of Health and Human Services (HHS) purchases GSK's A (H1N1) influenza antigen